Bullish
Eli Lilly breaks ground on $6.5B Houston plant to boost obesity drug production.
Eli Lilly has commenced construction on a $6.5 billion pharmaceutical manufacturing plant in Houston, Texas. The facility aims to produce active pharmaceutical ingredients, including those for Foundayo, Lilly's oral GLP-1 weight-loss drug. This expansion underscores Lilly's commitment to enhancing its obesity treatment portfolio and strengthening its manufacturing capabilities.
Key points
- Eli Lilly initiates $6.5 billion Houston plant to bolster obesity drug production.
- Governor Greg Abbott highlights the project's significance for Texas' life sciences sector.
- The Houston facility is expected to be completed by 2030.
Sources
AI-generated from public news sources. Not financial advice.
